tiprankstipranks
Tempest Therapeutics reports Q3 EPS (41c), consensus (36c)
PremiumThe FlyTempest Therapeutics reports Q3 EPS (41c), consensus (36c)
3M ago
Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
Premium
The Fly
Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
3M ago
Tempest Therpeutics options imply 22.5% move in share price post-earnings
Premium
The Fly
Tempest Therpeutics options imply 22.5% move in share price post-earnings
4M ago
Tempest Therapeutics appoints Sheldon Mullins as VP, regulatory affairs
PremiumThe FlyTempest Therapeutics appoints Sheldon Mullins as VP, regulatory affairs
5M ago
Tempest Therapeutics appoints Troy Wagner as VP, quality assurance
Premium
The Fly
Tempest Therapeutics appoints Troy Wagner as VP, quality assurance
6M ago
Tempest announces feedback form End-of-Phase 2 meeting with FDA for TPST-1120
Premium
The Fly
Tempest announces feedback form End-of-Phase 2 meeting with FDA for TPST-1120
6M ago
Tempest Therapeutics reports Q1 EPS (36c), consensus (37c)
PremiumThe FlyTempest Therapeutics reports Q1 EPS (36c), consensus (37c)
10M ago
Is TPST a Buy, Before Earnings?
Premium
Pre-Earnings
Is TPST a Buy, Before Earnings?
10M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100